Skip to main content
. 2019 May 21;8(8):3685–3697. doi: 10.1002/cam4.2244

Table 2.

Heatmap representing the cell‐free DNA (cfDNA) sample origin, the associated FFPE results (at initial diagnosis), as well cfDNA results: (a) the principal epidermal growth factor receptor (EGFR) mutation detected (at disease progression) and (b) the resistance mutation (at disease progression) detected with both the OncoBEAM™‐EGFR and the NGS‐56G assays for the whole cohort

3.2.